Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

• ClinicalTrials.gov Identifier: NCT02255461
• Recruitment Status: Terminated
• First Posted: October 2, 2014
• Results First Posted: April 8, 2020
• Last Update Posted: March 2, 2021
• Sponsor: Pediatric Brain Tumor Consortium
• Collaborator: National Cancer Institute (NCI)
• Information provided by (Responsible Party): Pediatric Brain Tumor Consortium

Study Description

Brief Summary:

This phase I trial studies the side effects and best dose of palbociclib isethionate in treating younger patients with central nervous system tumors that have grown, come back, or not responded to treatment. Palbociclib isethionate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Condition or disease	Intervention/treatment	Phase
Childhood Choroid Plexus Tumor; Childhood Ependymoblastoma; Childhood Grade III Meningioma; Childhood High-grade Cerebellar Astrocytoma; Childhood High-grade Cerebral Astrocytoma; Childhood Medulloepithelioma; Recurrent Childhood Anaplastic Astrocytoma; Recurrent Childhood Anaplastic Oligoastrocytoma; Recurrent Childhood Anaplastic Oligodendroglioma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Giant Cell Glioblastoma; Recurrent Childhood Glioblastoma; Recurrent Childhood Gliomatosis Cerebri; Recurrent Childhood Gliosarcoma; Recurrent Childhood Medulloblastoma; Recurrent Childhood Pineoblastoma; Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor	Drug: palbociclib isethionate; Other: pharmacological study; Other: laboratory biomarker analysis	Phase 1

Detailed Description:

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD)/phase II recommended dose and describe toxicities related to PD-0332991 (palbociclib isethionate) in children with retinoblastoma protein 1 (Rb1) positive recurrent, progressive or refractory primary central nervous system (CNS) tumors.

II. To determine plasma pharmacokinetics of PD-0332991 in children with Rb1positive recurrent, progressive or refractory primary CNS tumors.

SECONDARY OBJECTIVES:

I. To record preliminary evidence of efficacy of PD-0332991 in children with recurrent CNS tumors.

II. To evaluate cyclin-dependent kinase (CDK)4/6, cyclin D1-3, Ink4a-ARF copy-number variations in available tumor tissue by array comparative, genomic hybridization (aCGH).

III. To explore the potential relationships between the pharmacokinetics of PD-0332991 and pharmacodynamic response (e.g. percentage change in absolute neutrophil count [ANC], platelet counts).

IV. To explore the pharmacogenetic polymorphisms in PD-0332991 metabolizing enzymes and transporters and relate these polymorphisms to PD-0332991 pharmacokinetics.

OUTLINE: This is a dose-escalation study.

Patients receive palbociclib isethionate orally (PO) once daily (QD) on days 1-21. Treatment repeats every 4 weeks for 26 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 30 days.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 35 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors
• Actual Study Start Date: December 8, 2014
• Actual Primary Completion Date: February 25, 2019
• Actual Study Completion Date: February 25, 2019

Arms and Interventions

Arm	Intervention/treatment
Experimental: Treatment (palbociclib isethionate); Patients receive palbociclib isethionate PO QD on days 1-21. Treatment repeats every 4 weeks for 26 courses in the absence of disease progression or unacceptable toxicity.	Drug: palbociclib isethionate; Given PO; Other Name: 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one, 827022-33-3, palbociclib, PD 0332991-0054, PD-0332991, PD-332991, PF-00080665-73; Other: pharmacological study; Correlative studies; Other Name: pharmacological studies; Other: laboratory biomarker analysis; Correlative studies

Outcome Measures

Primary Outcome Measures :

1. Maximum Tolerated Dose (MTD) of Palbociclib in Stratum I [ Time Frame: 4 weeks ]
   Rolling-6 design was used to estimate MTD. The MTD was empirically defined as the highest dose level at which six patients were treated with at most one patient experiencing a dose-limiting toxicity (DLT) and the next higher dose level had been determined to be too toxic. Stratum I consisted of less-heavily pre-treated patients.
2. Maximum Tolerated Dose (MTD) of Palbociclib in Stratum II [ Time Frame: 4 weeks ]
   Rolling-6 design was used to estimate MTD. The MTD was empirically defined as the highest dose level at which six patients were treated with at most one patient experiencing a DLT and the next higher dose level had been determined to be too toxic. Stratum II consisted of heavily pre-treated patients.
3. Number of Patients Who Experienced Dose Limiting Toxicities (DLTs) [ Time Frame: 4 weeks ]
   DLTs were defined as any of the following adverse events that were at least possibly related to palbociclib that occurred during the first 4 weeks of therapy regardless of expectedness. Hematologic DLTs included grade 3 neutropenia with fever and sepsis, grade 3 thrombocytopenia and/or requiring a platelet transfusion on 2 separate days within a 7-day period, or any grade 4 hematologic toxicity except lymphopenia. Non-hematologic DLTs included any grade 4 non-hematologic toxicity, any grade 3 non-hematologic toxicity with some exceptions (e.g., nausea and vomiting of < 5 days; diarrhea and/or electrolyte disturbances which have not been maximally treated; AST/ALT elevation that returns to levels meeting eligibility criteria within 7 days of study drug interruption and does not recur upon restarting drug), or any grade 2 non-hematologic toxicity that persists for > 7 days and is considered medically significant or sufficiently intolerable by patients requires treatment interruption.
4. Single Dose Apparent Volume of Central Compartment (Vc/F) [ Time Frame: Up to day 3 ]
   On day 1 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 0.5, 1, 2, 4, 8 (±1), 10 (±0.5) optional, 24 (±4), 48 (±4) hours after the oral dose of palbociclib. Apparent volume of central compartment (Vc/F) was estimated using a non-compartmental method.
5. Single Dose Elimination Rate Constant (Ke) [ Time Frame: Up to day 3 ]
   On day 1 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 0.5, 1, 2, 4, 8 (±1), 10 (±0.5) optional, 24 (±4), 48 (±4) hours after the oral dose of palbociclib. Elimination rate constant (Ke) was estimated using a non-compartmental method.
6. Single Dose Half-life (t1/2) [ Time Frame: Up to day 3 ]
   On day 1 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 0.5, 1, 2, 4, 8 (±1), 10 (±0.5) optional, 24 (±4), 48 (±4) hours after the oral dose of palbociclib. Half-life (t1/2) was estimated using a non-compartmental method.
7. Single Dose Apparent Oral Clearance (CL/F) [ Time Frame: Up to day 3 ]
   On day 1 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 0.5, 1, 2, 4, 8 (±1), 10 (±0.5) optional, 24 (±4), 48 (±4) hours after the oral dose of palbociclib. Apparent oral clearance (CL/F) was estimated using a non-compartmental method.
8. Single Dose Area Under the Plasma Concentration Time Curve (AUC) [ Time Frame: Up to day 3 ]
   On day 1 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 0.5, 1, 2, 4, 8 (±1), 10 (±0.5) optional, 24 (±4), 48 (±4) hours after the oral dose of palbociclib. Area under the plasma concentration time curve (AUC) was estimated using a non-compartmental method.
9. Steady State Apparent Volume of Central Compartment (Vc/F) [ Time Frame: Up to day 22 ]
   On day 21 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 1, 2, 4, 8 (±1), 10 (±0.5) optional, and 24 (±4) hours after the dose. Apparent volume of central compartment (Vc/F) was estimated using a non-compartmental method.
10. Steady State Elimination Rate Constant (Ke) [ Time Frame: Up to day 22 ]
    On day 21 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 1, 2, 4, 8 (±1), 10 (±0.5) optional, and 24 (±4) hours after the dose. Elimination rate constant (Ke) was estimated using a non-compartmental method.
11. Steady State Half-life (t1/2) [ Time Frame: Up to day 22 ]
    On day 21 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 1, 2, 4, 8 (±1), 10 (±0.5) optional, and 24 (±4) hours after the dose. Half-life (t1/2) was estimated using a non-compartmental method.
12. Steady State Apparent Oral Clearance (CL/F) [ Time Frame: Up to day 22 ]
    On day 21 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 1, 2, 4, 8 (±1), 10 (±0.5) optional, and 24 (±4) hours after the dose. Apparent oral clearance (CL/F) was estimated using a non-compartmental method.
13. Steady State Area Under the Plasma Concentration Time Curve (AUC) [ Time Frame: Up to day 22 ]
    On day 21 of course 1, series blood samples for palbociclib pharmacokinetic studies were collected at pre-dose, 1, 2, 4, 8 (±1), 10 (±0.5) optional, and 24 (±4) hours after the dose. Area under the plasma concentration time curve (AUC) was estimated using a non-compartmental method.

Secondary Outcome Measures :

1. Number of Subjects With Objective Responses [ Time Frame: Up to 2 years ]
   Objective responses included complete response (CR) and partial response (PR).
2. Association Between Neutropenia and Single Dose Palbociclib AUC [ Time Frame: Up to approximately 4 weeks ]
   Neutrophil count decreased adverse events observed in course 1 that were at least possibly attributable to palbociclib were included in analysis. Based on the highest toxicity grade reported, all participants, irrespective of their dose level or stratum, were combined and classified into three categories: 0 = no toxicity reported, 1 = grade 1 or 2, and 2 = grade 3 or 4. Association between neutrophil count decreased and single dose palbociclib AUC for all participants was examined.
3. Association Between Lymphopenia and Single Dose Palbociclib AUC [ Time Frame: Up to approximately 4 weeks ]
   Lymphocyte count decreased adverse events observed in course 1 that were at least possibly attributable to palbociclib were included in analysis. Based on the highest toxicity grade reported, all participants, irrespective of their dose level or stratum, were combined and classified into three categories: 0 = no toxicity reported, 1 = grade 1 or 2, and 2 = grade 3 or 4. Association between Lymphocyte count decreased and single dose palbociclib AUC for all participants was examined.
4. Association Between Leukopenia and Single Dose Palbociclib AUC [ Time Frame: Up to approximately 4 weeks ]
   White blood cell count decreased adverse events observed in course 1 that were at least possibly attributable to palbociclib were included in analysis. Based on the highest toxicity grade reported, all participants, irrespective of their dose level or stratum, were combined and classified into three categories: 0 = no toxicity reported, 1 = grade 1 or 2, and 2 = grade 3 or 4. Association between white blood cell count decreased and single dose palbociclib AUC for all participants was examined.

Other Outcome Measures:

1. Number of Subjects With Cyclin-dependent Kinase-4 (CDK4) Copy Number Variations [ Time Frame: At enrollment ]
   CDK4 is a key component in signaling pathways inside normal cells and cancer cells. CDK4 copy number variations were to be assessed by array comparative genomic hybridization in available tumor tissues from consenting patients.
2. Number of Subjects With Cyclin-dependent Kinase-6 (CDK6) Copy Number Variations [ Time Frame: At enrollment ]
   CDK6 is a key component in signaling pathways inside normal cells and cancer cells. CDK6 copy number variations were to be assessed by array comparative genomic hybridization in available tumor tissues from consenting patients.
3. Number of Subjects With Cyclin D1 Copy Number Variations [ Time Frame: At enrollment ]
   Cyclin D1 is a key component in signaling pathways inside normal cells and cancer cells. Cyclin D1 copy number variations were to be assessed by array comparative genomic hybridization in available tumor tissues from consenting patients.
4. Number of Subjects With Cyclin D2 Copy Number Variations [ Time Frame: At enrollment ]
   Cyclin D2 is a key component in signaling pathways inside normal cells and cancer cells. Cyclin D2 copy number variations were to be assessed by array comparative genomic hybridization in available tumor tissues from consenting patients.
5. Number of Subjects With Cyclin D3 Copy Number Variations [ Time Frame: At enrollment ]
   Cyclin D3 is a key component in signaling pathways inside normal cells and cancer cells. Cyclin D3 copy number variations were to be assessed by array comparative genomic hybridization in available tumor tissues from consenting patients.
6. Number of Subjects With Ink4a-ARF Loss Copy Number Variations [ Time Frame: At enrollment ]
   Ink4a-ARF is a key component in signaling pathways inside normal cells and cancer cells. Ink4a-ARF loss copy number variations were to be assessed by array comparative genomic hybridization in available tumor tissues from consenting patients.
7. Polymorphisms in Efflux-transporter Proteins P-glycoprotein (P-gp; ABCB1) [ Time Frame: At enrollment ]
   Polymorphisms in ABCB1 encode for efflux-transporter proteins P-glycoprotein (P-gp), for which palbociclib has been shown as a substrate. Genomic DNA was to be isolated from peripheral blood samples from consenting patients to determine ABCB1 polymorphisms.
8. Polymorphisms in Breast Cancer Resistance Protein (BCRP; ABCG2) [ Time Frame: At enrollment ]
   Polymorphisms in ABCG2 encode for BCRP, for which palbociclib has been shown as a substrate. Genomic DNA was to be isolated from peripheral blood samples from consenting patients to determine ABCG2 polymorphisms.

Eligibility Criteria

• Ages Eligible for Study: 4 Years to 21 Years (Child, Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Patients with retinoblastoma protein (Rb1) positive recurrent, progressive or refractory central nervous system (CNS) tumors
• Histologically confirmed Rb1 positive primary recurrent, progressive, or refractory central nervous system tumors; patients with low grade gliomas are excluded
• Formalin fixed paraffin embedded tumor tissue (preferably from current recurrence) must be available to assess Rb1 protein status prior to enrollment; only patients with recurrent diffuse intrinsic brain stem glioma (DIPG) can be enrolled without the need for available tumor tissue for Rb1 protein status confirmation
• Patients must have measurable disease (in 2-dimensions) on magnetic resonance imaging (MRI) scan of brain and/or spine to assess preliminary evidence of response

• Body surface area (BSA):

  • Patients enrolled on dose level 1 (50 mg/m^2) must have BSA >= 1.20 m^2
  • Patients enrolled on dose level 2 (75 mg/m^2) must have BSA >= 0.93 m^2
  • Patients enrolled on dose level 3 (95 mg/m^2) must have BSA >= 0.70 m^2
• Patients must have received no more than 2 prior chemotherapy regimens and/or focal radiotherapy for their brain tumor and fully recovered from the acute treatment related toxicities of all prior therapies prior to entering this study; for those acute baseline adverse events attributable to prior therapy, patients must meet organ function criteria
• Chemotherapy: patients must have received their last dose of known myelosuppressive anticancer chemotherapy at least three (3) weeks prior to study enrollment in the study or at least six (6) weeks for those receiving nitrosourea
• Biologic therapy: patients should have received their last dose of biologic agent >= 7 days prior to enrollment; in the event the patient has received another biologic agent and has experienced >= grade 2 myelosuppression, then at least three (3) weeks must have elapsed prior to enrollment; if the investigational or biologic agent has a prolonged half-life then at least three (3) weeks interval is required

• Radiotherapy: patients must have had their last fraction of:

  * Focal irradiation > 2 weeks prior to enrollment

• Corticosteroids: patients who are receiving dexamethasone or other corticosteroids must be on a stable or decreasing dose for at least 1 week prior to enrollment; it is recommended that patients be off all steroid therapy or receive the least dose that will control their neurologic symptoms
• Growth factors: all colony forming growth factor(s) have been discontinued for at least one week prior to enrollment (filgrastim, sargramostim, and erythropoietin); for patients on long acting growth factors, the interval should be two weeks
• Patients with neurological deficits that are stable for a minimum of one week prior to registration
• Patients must be able to swallow capsules
• Karnofsky performance scale (KPS for > 16 years of age) or Lansky performance score (LPS for =< 16 years of age) assessed within two weeks of enrollment must be >= 60
• Absolute neutrophil count >= 1,000/mm^3
• Platelets >= 100,000/mm^3 transfusion independent (no platelet transfusion one week prior to enrollment)
• Hemoglobin >= 8 g/dl
• Total bilirubin =< 1.5 times upper limit of institutional normal (ULN) for age
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional upper limit of normal for age
• Serum albumin >= 3 g/dL

• Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 ml/min/1.73 m^2 or a serum creatinine based on age/gender as follows:

  • 1 to < 2 years: 0.6 (male), 0.6 (female)
  • 2 to < 6 years: 0.8 (male), 0.8 (female)
  • 6 to < 10 years: 1 (male), 1 (female)
  • 10 to < 13 years: 1.2 (male), 1.2 (female)
  • 13 to < 16 years: 1.5 (male), 1.4 (female)
  • >= 16 years: 1.7 (male), 1.4 (female)
• Female patients of childbearing potential must have a negative serum pregnancy test at the time of enrollment
• Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control while being treated on this study
• Patient and/or guardian have the ability to understand and the willingness to sign a written informed consent document according to institutional guidelines

Exclusion Criteria:

• Patients with any clinical significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction) that is likely to interfere with the study procedures or results
• Patients with low grade gliomas and Rb1 negative tumors

• Patients who have received any of the following:

  • > 2 chemotherapy regimens
  • Myeloablative chemotherapy with stem cell rescue
  • Craniospinal irradiation
• Patients with corrected QT (QTc) interval of > 450 msec or those on medications known to prolong QTc interval
• Prior treatment on a CDK inhibitor
• Patients who are receiving drugs that are strong inducers or inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)
• Patients who are receiving any other investigational therapy
• Patients who require enzyme inducing anti-convulsants to control seizures
• Patients with cataracts on ophthalmologic examination

Contacts and Locations

Locations

United States, California

Childrens Hospital Los Angeles

Los Angeles, California, United States, 90027

Lucile Packard Children Hospital Stanford University

Palo Alto, California, United States, 94304

United States, District of Columbia

Childrens National Medical Center

Washington, District of Columbia, United States, 20010-2970

United States, Illinois

Lurie Childrens Hospital-Chicago

Chicago, Illinois, United States, 60614

United States, New York

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065

United States, North Carolina

Duke University Medical Center

Durham, North Carolina, United States, 27710

United States, Ohio

Cincinnati Children Hospital Medical Center

Cincinnati, Ohio, United States, 45229

United States, Pennsylvania

Children Hospital of Pittsburgh of UPMC

Pittsburgh, Pennsylvania, United States, 15224

United States, Tennessee

St. Jude Children Research Hospital

Memphis, Tennessee, United States, 38105

United States, Texas

Texas Childrens Hospital

Houston, Texas, United States, 77030

United States, Washington

Seattle Children Hospital

Seattle, Washington, United States, 98105

Sponsors and Collaborators

Pediatric Brain Tumor Consortium

National Cancer Institute (NCI)

Investigators

• Principal Investigator: David Van Mater, MD; Pediatric Brain Tumor Consortium

  Study Documents (Full-Text)

Documents provided by Pediatric Brain Tumor Consortium:

Informed Consent Form  [PDF] June 28, 2018

Study Protocol and Statistical Analysis Plan  [PDF] June 28, 2018

More Information

• Responsible Party: Pediatric Brain Tumor Consortium
• ClinicalTrials.gov Identifier: NCT02255461
• Other Study ID Numbers: PBTC-042; U01CA081457 ( U.S. NIH Grant/Contract )
• First Posted: October 2, 2014
• Results First Posted: April 8, 2020
• Last Update Posted: March 2, 2021
• Last Verified: February 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes

Additional relevant MeSH terms:

Neoplasms; Glioblastoma; Astrocytoma; Meningioma; Gliosarcoma; Nervous System Neoplasms; Medulloblastoma; Central Nervous System Neoplasms; Oligodendroglioma; Neuroectodermal Tumors; Neuroectodermal Tumors, Primitive; Choroid Plexus Neoplasms; Pinealoma; Neoplasms, Neuroepithelial; Recurrence; Disease Attributes; Pathologic Processes; Glioma; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Neoplasms, Vascular Tissue; Meningeal Neoplasms; Neoplasms by Site; Nervous System Diseases; Cerebral Ventricle Neoplasms; Brain Neoplasms; Brain Diseases; Central Nervous System Diseases